Deals
After debuting on the public markets with $256.3 million and raking in an additional $472 million, Veradermics has emerged as one of biotech’s biggest post-IPO standouts. CEO Reid Waldman credits the weight loss craze for establishing consumer-driven channels.
FEATURED STORIES
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
While merger and acquisition activity has been robust of late, frequent changes in guidance and leadership at the regulator add risk to any transaction.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Many mergers took place in 2021. Here’s a look at some of the hottest life sciences SPAC merger announcements so far in 2021. Many mergers took place in 2021,
The merger between Blade Therapeutics and Biotech Acquisition Company will provide the company with $254.3 million to drive the development of cudetaxestat.
For the past 20 years, Novartis has held a 33% stake in Roche, its Basel, Switzerland neighbor. Now, Novartis has divested its one-third stake to Roche for a whopping $20.7 billion.
Shoreline Biosciences secured $140 million in financing to accelerate the growth of its induced pluripotent stem cells (iPSC)-based immunotherapies and support the expansion of its manufacturing capabilities.
Monday was a big day for LianBio, as the Shanghai-based company launched on the Nasdaq with an impressive $325 million initial public offering (IPO).
Novartis has forged a collaboration with U.K.-startup Dunad Therapeutics to develop next-generation targeted protein-degradation therapies in a deal valued at up to $1.3 billion.
GlaxoSmithKline denied reports that they were interested in acquiring Canada’s Aurinia Pharmaceuticals, although some reports claim they are preparing to bid.
One year after snagging $310 million in a financing round, LianBio raised $325M in its initial public offering. Its stock begins selling today on Nasdaq under the ticker symbol “LIAN.”
The decision came after Avoro Capital Advisors, which owns a 7% stake in Acceleron, posted its objections to the deal.
The deal was struck one month after GammaDelta dosed its first patient in a Phase I acute myeloid leukemia (AML) trial.